bioAffinity Technologies, Inc.
BIAF- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001712762
No open-market purchases or sales by bioAffinity Technologies, Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $782.5K in total; no superinvestor holds it.
Other share classesBIAFW
Q1 2023 vs. Q4 2022
How the institutions holding bioAffinity Technologies, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 5 | 6 | +1 |
| Shares | 83.5K | 102.4K | +18.9K (+22.7%) |
| Value | $133.5K | $193.5K | +$59.9K (+44.9%) |
New holders (3)
Institutions that held bioAffinity Technologies, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Captrust Financial Advisors | 43,642 | $82.5K | 0.00% |
| Two Sigma Investments, LP | 26,587 | $50.2K | 0.00% |
| State Street Corp | 17,600 | $33.3K | 0.00% |
Sold out (2)
Institutions that held bioAffinity Technologies, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Financial Engines Advisors L.L.C. | 64,749 | $103.6K |
| Morgan Stanley | 3 | $5 |